6.ดร.ภญ.รัชนีกร เจวประเสริฐพันธุ์_From Hope to Innovation The GPO Journey on HIV Treatment.pdf

1、From Hope to Innovation:The GPO Journey on HIV TreatmentAssistant Managing Director of GPODr.Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization CONTENTSCurrent Situation of HIV in ThailandO1O230 Years Roadmap of GPOs ARV ProductsO3Thai HIV Treatment/Prevention Guideline 2025O4O5K

2、ey Success FactorsChallenges&RecommendationCurrent Situation of HIV/AIDS in Thailand|2024AIDs-related death9,100500,000(88.0%)-1,9008,100-1,100570,000People living with HIVNew HIV infectionPeople accessed treatmentDecreasing HIV new cases in Thailand 1990-2024+42,867+10,000https:/aidsinfo.unaids.org

3、/https:/www.aidsdatahub.org/resource/thailand-country-snapshot-2023GPOs HIV/AIDS Pharmaceutical Revolution1981LATE1980SMID1990S2012-20252025First AIDS caseOne/two ARVs Improve survival Few ARVs High toxicityThree ARVs(HAART)More class ARVs More potent drug Moderate toxicityThree ARVs(HAART)More new

4、ARVs Convenient regimen(FDC)Single tablet Low toxicityNew strategies Long-acting ARVs Monthly,6-monthly,Yearly ARVs Cure?30 years Roadmap of GPOs ARV products19952000200120022004200620072008201120122013201420172018201920212023202520262029ANTIVIR(Zidovudine)STAVIRLAMIVIRGPO-VIR S30(NVP/3TC/d4T)ANTIVI

5、R syrup STAVIR solutionLAMIVIR syrupNERAVIRGPO-VIR Z250(NVP/3TC/AZT)LAMIVIRLAHEPDIVIRRINAVIR solutionINAVIRLASTAVIRDIVIRZILAVIR(AZT/3TC)Lopinavir/Ritonavir solutionNERAVIR suspensionLopinavir/RitonavirTENO-EM(PrEP)EFAVIRENZTenofovir GPOTENEVIRABACAVIREFAVIRENZRINAVIRDARUTABGPO-VIR T(EFV/FTC/TD)ABACA

6、VIR solutionALACOVIRDOLUGRASEDALAVIR(DTG/3TC/TDF)TENO-AFTEDAVIR(DTG/FTC/TAF)TAF-EM(PrEP)LAMIGRASE(DTG/3TC)Long-acting productRecommended RegimenAlternative RegimenThai HIV Treatment Guideline 2025 and Related GPOs ARV Products TXF/XTC/INSTIs(BIC or DTG)or DTG/3TC TXF/XTC+NNRTIs(E